KEYWORDS
degradomics, protease, proteomics, skin, wound healing
Proteases play pivotal roles in many diseases and form 5-10% of all potential drug targets. It is now clear that detrimental proteolysis results from perturbation of a complex proteolytic network rather than altered activity of a single enzyme. Disturbances of such networks lead to severe diseases including cancer and inflammatory disorders. However, so far technical limitations prohibited a global understanding of interconnected protease activity in complex systems, contributing to devastating failures of protease inhibitors in clinical trials.
Our research group develops and applies novel proteomics technologies to understand protease networks in inflamed tissues and hyperproliferative epithelia focusing on the skin as model system. Targeted assays discriminate pro- from active proteases, and our next-generation positional proteomics workflows allow analyzing small sample amounts from cells and tissues obtained from animal models and patient biopsies.
In translational research, we monitor and functionally characterize protease substrate cleavages as net outcomes of complex proteolytic activities in healing impairments, a common complication in elderly people and patients suffering from diabetes. In collaboration with clinicians, we apply approaches that we have implemented using clinically relevant wound models to the analysis of wound samples from patients with normal and delayed healing.
Prof. Ulrich auf dem Keller
Please contact SKINTEGRITY.CH coordinator
Dr. Maarten Schledorn with any questions
or inquiries.
Email
SKINTEGRITY.CH Principal Investigators are in bold: